Libradin (Barnidipine Hydrochloride)

Barnidipine Hydrochloride is used to manage arterial hypertension, a condition characterized by elevated systemic blood pressure.

• Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
• Secondary hypertension (as adjunct): may be added to other antihypertensives when blood pressure remains uncontrolled.
• Isolated systolic hypertension in the elderly: helps reduce elevated systolic pressure.

• Barnidipine Hydrochloride selectively blocks L‑type calcium channels in vascular smooth muscle. By inhibiting calcium influx, it prevents contraction of arterial smooth muscle, producing dose‑dependent vasodilation. The resulting decrease in peripheral vascular resistance lowers systemic blood pressure without significant effect on cardiac conduction or contractility. The drug’s high affinity for arterial tissue contributes to a prolonged antihypertensive effect and a favorable tolerability profile compared with non‑selective calcium antagonists.

Barnidipine Hydrochloride may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Headache: mild to moderate headache, often transient.
• Flushing: transient facial warmth or redness.
• Peripheral edema: swelling of ankles or feet, especially after prolonged standing.
• Dizziness: light‑headedness, particularly on standing quickly.
• Tachycardia: increased heart rate, usually without other symptoms.
• Nausea: mild gastrointestinal upset, may be accompanied by loss of appetite.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that can cause fainting.
• Angioedema: swelling of lips, tongue, or airway requiring immediate medical attention.
• Myocardial infarction: chest pain or discomfort indicating a possible heart attack.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Severe bradycardia: markedly slow heart rate that may lead to dizziness.
• Anaphylactic reaction: life‑threatening allergic response with rash, difficulty breathing, and shock.

When prescribing Barnidipine Hydrochloride, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: dose adjustment may be required in patients with severe kidney dysfunction.
• Hepatic disease: use with caution in patients with liver impairment.
• Concomitant antihypertensives: monitor for additive blood pressure lowering.
• Elderly patients: start at low dose and monitor for orthostatic hypotension.
• Pregnancy and lactation: safety not established; avoid unless clearly needed.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Barnidipine Hydrochloride can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels, risking toxicity.
• Simultaneous use with other calcium channel blockers: can cause excessive vasodilation and hypotension.

Moderate Interactions (Monitor Closely)

• β‑blockers: additive effect on blood pressure and heart rate.
• Diuretics: may enhance hypotensive effect, monitor electrolytes.
• NSAIDs: may reduce antihypertensive efficacy.
• Grapefruit juice: can increase drug exposure modestly.